New chemotherapy combinations for advanced bladder cancer
1Medical Oncology Service, General University Vall d'Hebron Hospital, Barcelona, Spain. bellmunt@hg.vhebron.es
Current Opinion in Urology
|August 9, 2001
Summary
Transitional cell carcinoma of the urothelium is a chemosensitive cancer. New agents like gemcitabine and taxanes offer promise, but phase II data requires confirmation in phase III trials for urothelial cancer treatment.
Area of Science:
- Urothelial Carcinomas
- Medical Oncology
- Chemotherapy
Background:
- Transitional cell carcinoma of the urothelium is a chemosensitive malignancy.
- The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) was the standard treatment.
- Recent advancements introduced new chemotherapeutic agents.
Purpose of the Study:
- To evaluate the efficacy of novel chemotherapeutic agents in treating transitional cell carcinoma of the urothelium.
- To explore new perspectives beyond the standard MVAC regimen.
Main Methods:
- Review of preliminary phase II clinical trial data.
- Assessment of new chemotherapeutic agents including gemcitabine and taxanes.
Main Results:
- New agents like gemcitabine and taxanes show promise in treating urothelial cancer.
- Preliminary data suggests potential improvements over the traditional MVAC regimen.
Conclusions:
- Novel chemotherapeutic agents present promising new treatment options for transitional cell carcinoma of the urothelium.
- Further validation through well-designed phase III clinical trials is essential to confirm these findings.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
556
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
556
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
496
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
496